While the exact mechanisms of ischemia/reperfusion injury remain unclear, our laboratory and others have shown that inhibition of complement activation (e.g., sCR1 or C1 esterase inhibitor), depletion of complement components (e.g., cobra venom factor) and genetically deficient complement component (e.g., C3, C4, MBL, factor D, C1qa) mice have revealed an important role of complement and the specific pathways involved in ischemia/reperfusion injury. During the last funding cycle, we demonstrated that inhibition of mannose binding lectin (MBL) protected the ischemic gastrointestinal system from the primary ischemic event. In contrast, the pulmonary system, which takes a second hit from the primary ischemic gastrointestinal tract, was not protected. Further, complement activation in the lung was observed in C1qa deficient, as well as MBL deficient mice, but not in C2/factor B deficient (KO) mice. Addition of C2 restored the complement activation and tissue inflammation/injury in the C2/fB KO mice following gastrointestinal ischemia/reperfusion (GI/R). These data suggest that a C2 dependent, C1q and MBL independent process is responsible for the complement activation, inflammation and injury following GI/R. Preliminary data, using novel ficolin A KO mice, suggest that this complement activating lectin, ficolin-A, is the initiating molecule responsible for complement activation in the lungs following GI/R. We have also generated novel MBL-A/-C/ficolin-A KO mice for the proposed studies in assessing the role of ficolin-A in pulmonary inflammation and complement deposition following GI/R. Preliminary studies demonstrate biological evidence of a C2 and C4 bypass mechanism for activation of the alternative complement pathway by the MBL complex. One potential molecular mechanism of this bypass involves activation of the coagulation system. Preliminary data demonstrates multiple interactions of the MBL complex with several coagulation proteins. These data demonstrate that simple inhibition of complement in vivo may need a much better understanding of the complex interactions of complement with the coagulation system, an aim of this competitive renewal. In this competitive renewal, we will continue to investigate the molecular mechanisms involved in complement activation during oxidative stress of endothelial cells in vitro and in vivo. The general aim of our laboratory is to characterize the molecular mechanisms governing complement activation during endothelial oxidative stress.

Public Health Relevance

Ischemia of the gastrointestinal system leads to increased morbidity and mortality. This grant seeks to establish the role of a novel lectin, ficolin-A, in the pulmonary injury observed following gastrointestinal ischemia, while also investigating the connections between the lectin complexes and the coagulation system. The preliminary data demonstrate the importance of selecting the appropriate complement inhibitor for human disease because of the connectivity observed in these two cascade systems: complement and coagulation

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56HL056086-14
Application #
7920719
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Schwartz, Lisa
Project Start
1996-05-01
Project End
2010-08-31
Budget Start
2009-09-30
Budget End
2010-08-31
Support Year
14
Fiscal Year
2009
Total Cost
$445,000
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Ozaki, Masayuki; Kang, Yulin; Tan, Ying Siow et al. (2016) Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. Kidney Int 90:774-82
Tong, Hua Hua; Lambert, Garrett; Li, Yong Xing et al. (2014) Deletion of the complement C5a receptor alleviates the severity of acute pneumococcal otitis media following influenza A virus infection in mice. PLoS One 9:e95160
Harboe, Morten; Garred, Peter; Lindstad, Julie K et al. (2012) The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol 189:2606-13
Zou, Chenhui; La Bonte, Laura R; Pavlov, Vasile I et al. (2012) Murine hyperglycemic vasculopathy and cardiomyopathy: whole-genome gene expression analysis predicts cellular targets and regulatory networks influenced by mannose binding lectin. Front Immunol 3:
Li, Qian; Li, Yong Xing; Douthitt, Kelsey et al. (2012) Role of the alternative and classical complement activation pathway in complement mediated killing against Streptococcus pneumoniae colony opacity variants during acute pneumococcal otitis media in mice. Microbes Infect 14:1308-18
Orsini, Franca; Villa, Pia; Parrella, Sara et al. (2012) Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation 126:1484-94
Stahl, Gregory L; Shernan, Stanton K; Smith, Peter K et al. (2012) Complement activation and cardiac surgery: a novel target for improving outcomes. Anesth Analg 115:759-71
La Bonte, Laura R; Pavlov, Vasile I; Tan, Ying S et al. (2012) Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol 188:885-91
Pavlov, Vasile I; Skjoedt, Mikkel-Ole; Siow Tan, Ying et al. (2012) Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation 126:2227-35
Pavlov, Vasile I; La Bonte, Laura R; Baldwin, William M et al. (2012) Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications. Am J Pathol 180:104-12

Showing the most recent 10 out of 19 publications